Search
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsPertussis vaccine
go.drugbank.com/drugs/DB15274ApprovedInvestigationalPertussis vaccine is under investigation in clinical trial NCT01698346 (Pertussis (Tdap) Vaccination in Pregnancy).
Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, dTaP Booster Injektionssuspension in einer FertigspritzeLactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedA normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. … Lactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]
Mixtures: Dextrose in Lactated Ringers, D5-LRI (5% DEXTROSE IN LOCTATED RINGER'S INJ.)Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalUS in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalIt was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
Ribavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalas an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. … Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Ferric carboxymaltose
go.drugbank.com/drugs/DB08917ApprovedInvestigationalFerric carboxymaltose is an iron replacement product and, chemically, an iron-carbohydrate complex. It was FDA approved on July 25, 2013.
Categories: Compounds used in a research, industrial, or household settingLifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Categories: Compounds used in a research, industrial, or household settingHuman thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalChinese hamster ovary cell line [FDA Label]. … In particular, while human thrombin products are made from pooled human source plasma, recombinant thrombin is a human coagulation protein produced via recombinant DNA technology from a genetically modified
Mixtures: EVICEL Fibrin Sealant (Human) Solution, 50-90 mg/ml, 800-1200 IU/mlKetoconazole
go.drugbank.com/drugs/DB01026ApprovedInvestigational[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.